Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merrimack Pharma

- PMLiVE

AZ drug matched to cancer mutation passes phase 2 test

More data from promising class of targeted small molecule drugs

- PMLiVE

Soon-Shiong presents first data on cancer memory vaccine at SITC

Novel cocktail shows modest gains in prostate cancer

- PMLiVE

Democrats regain control of House in mid-terms

Biotech and pharma share price indexes have climbed since the news broke

- PMLiVE

Pfizer claims rapid FDA nod for Lorbrena

Green light is latest in a string of cancer drug approvals

- PMLiVE

Is GSK planning to exit the respiratory business?

Oncology head says opportunities diminishing despite firm's heritage

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

- PMLiVE

US says medicine ads should include list prices

Hopes the proposal will encourage lower prescription drug prices

- PMLiVE

Cancer care – the power of new technologies

With patient numbers set to soar, how can we make a difference?

- PMLiVE

AcelRX’s potent opioid tablets set to win FDA backing for pain relief

Panel voted 10 to 3 in favour of the treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links